Incretin Axis (GLP-1, GIP)

The incretin axis is the hormonal circuit linking nutrient absorption in the gut to amplified insulin secretion from pancreatic beta cells. Two gut-derived peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released within minutes of a meal and collectively account for 50-70% of postprandial insulin output, a phenomenon termed the incretin effect. (PMID 17098089) The receptors for both hormones belong to the class B1 GPCR subfamily and signal through overlapping but distinct intracellular cascades that extend beyond the pancreas to the brain, cardiovascular system, adipose tissue, and bone.

Pathway Components

Ligand Biosynthesis and Secretion

GLP-1

GLP-1 is a 30- or 31-amino-acid peptide produced by tissue-specific post-translational processing of proglucagon, encoded by the GCG gene (human chromosome 2q24.2, UniProt P01275). In the gut and brainstem, proglucagon is cleaved by prohormone convertase 1/3 (PCSK1) to yield glicentin, oxyntomodulin, GLP-1, and GLP-2. The biologically active forms are GLP-1 (7-37) and the more abundant GLP-1 (7-36) amide, the latter generated by C-terminal amidation. In humans, more than 80% of secreted GLP-1 is in the amidated form. (PMID 17098089)

GLP-1 is secreted by intestinal L-cells, a subset of enteroendocrine cells concentrated in the distal ileum and colon. L-cells are electrically active epithelial sensory cells. Luminal glucose activates sodium-glucose cotransporter 1 (SGLT1, SLC5A1) and generates membrane depolarization; fatty acids and amino acids activate G protein-coupled receptors including GPR40 (FFAR1), GPR41 (FFAR3), and GPR119, all of which converge on elevation of intracellular calcium to trigger GLP-1 exocytosis. Neural inputs via the enteric and vagal nervous systems provide additional stimulatory drive.

Once released, GLP-1 is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4, DPP4, UniProt P27487), a serine protease expressed on endothelial surfaces adjacent to L-cells. DPP-4 cleaves the Ala8-Glu9 bond to produce the inactive GLP-1 (9-36) amide. Less than 25% of secreted GLP-1 exits the intestinal mucosa intact; of the remainder, 40-50% is cleared across the hepatic portal bed, leaving only 10-15% of total secreted GLP-1 in peripheral circulation with a plasma half-life of approximately 2 minutes. (PMID 17098089)

GIP

GIP is a 42-amino-acid peptide encoded by the GIP gene (human chromosome 17q21.32, UniProt P09681). It is produced by intestinal K-cells, which are densely concentrated in the duodenum and proximal jejunum. K-cells respond primarily to dietary fat and glucose, secreting GIP within 15-30 minutes of meal onset.

Like GLP-1, GIP is rapidly cleaved by DPP-4. Its plasma half-life is 5-7 minutes in healthy individuals but may extend to 5-7 minutes in patients with type 2 diabetes (T2D), where elevated circulating GIP does not translate to normal insulinotropic activity, consistent with receptor-level desensitization. (PMID 24296715)

Receptors

Both incretin receptors are class B1 (secretin-family) GPCRs defined by a large extracellular N-terminal domain that participates in peptide binding, a transmembrane bundle that couples to Gs, and an intracellular C-terminal tail that binds beta-arrestins.

GLP1R (P43220) is a 463-amino-acid, 7-transmembrane receptor. Its crystal and cryo-EM structures reveal that GLP-1 engages both the extracellular domain (the “stalk”) and the extracellular loops of the transmembrane core in a two-domain binding mode. Within the pancreatic islet, GLP1R expression is substantially restricted to beta cells; this cell-type specificity contrasts with GIPR, which is expressed in alpha cells, beta cells, and possibly delta cells. (PMID 35065096)

GIPR (P48546) exists as two isoforms: a 466-amino-acid short form and a 493-amino-acid long form carrying 27 additional residues at the transmembrane 7 / C-tail junction. Both isoforms bind GIP with high, comparable affinity and produce dose-dependent cAMP accumulation. A distinguishing feature of GIPR versus GLP1R pharmacology is attenuated ligand-induced desensitization and internalization: GIPR endocytosis requires beta-arrestin 2 scaffolding, whereas GLP1R can internalize in its absence. (PMID 35065096)

Downstream Signaling

Canonical Gs/cAMP/PKA/Epac2 Cascade

Ligand binding to either receptor stabilizes an active receptor conformation that enables exchange of GDP for GTP on the Galpha-s subunit and dissociation of Gbetagamma.

1. Active Galpha-s stimulates adenylyl cyclase (ADCY isoforms, predominantly ADCY5 and ADCY6 in beta cells) to convert ATP to cyclic AMP (cAMP).
2. Elevated cAMP binds two parallel effectors in the beta cell:
   • Protein kinase A (PKA; catalytic subunits PRKACA/B, UniProt P17612/P22694). PKA phosphorylates ion channels, vesicle docking machinery, and the transcription factor CREB (CREB1, UniProt P16220) at Ser133. Phospho-CREB recruits CBP/p300 and drives expression of genes sustaining beta-cell identity, including PDX1, NKX6-1, and insulin itself.
   • Exchange protein directly activated by cAMP 2 (Epac2, RAPGEF4, UniProt O14827). Epac2 activates the small GTPase Rap1, which closes ATP-sensitive potassium channels (KATP, formed by Kir6.2/KCNJ11 and SUR1/ABCC8) independently of PKA. KATP closure depolarizes the beta-cell plasma membrane.
3. Membrane depolarization triggers opening of voltage-gated L-type calcium channels (Cav1.2/CACNA1C and Cav1.3/CACNA1D), raising cytoplasmic Ca2+ and driving insulin granule exocytosis through the SNARE complex (SNAP25/syntaxin-1/VAMP2).

The combination of PKA-dependent phosphorylation of docking proteins (including RIM2 and Munc13-1) and Epac2-mediated Rap1 activation sets the releasable pool of insulin granules. The net effect is glucose-dependent insulin secretion: in the absence of glucose-driven KATP closure, incretin-stimulated cAMP accumulation produces only modest insulin release, providing the “dependency” that prevents hypoglycemia during fasting. (PMID 35065096)

Additional Signaling Arms

Beyond Gs, GLP1R and GIPR each engage secondary effectors.

Biased agonism at GLP1R, meaning preferential activation of one signaling branch over another, is pharmacologically achievable and has become a design goal for next-generation compounds. Tirzepatide, for example, acts as a functionally biased GLP-1R agonist that produces less beta-arrestin recruitment per unit of cAMP than endogenous GLP-1, which may contribute to its distinct weight-loss profile. (PMID 36050763)

Signal Flow Diagram

flowchart TD
    subgraph Ligands["Intestinal Hormone Secretion"]
        K["K-cell (duodenum / jejunum)"]
        L["L-cell (ileum / colon)"]
        GIP_lig["GIP (1-42)\nGene: GIP, UniProt P09681"]
        GLP1_lig["GLP-1 (7-36 amide)\nGene: GCG, UniProt P01275"]
        DPP4["DPP-4 cleavage\nGene: DPP4, UniProt P27487\nt1/2 ~2 min (GLP-1)\nt1/2 ~5-7 min (GIP)"]
    end

    subgraph Receptors["Incretin Receptors (Class B1 GPCRs)"]
        GIPR_r["GIPR (P48546)\nBeta cells, alpha cells\nadipose, bone"]
        GLP1R_r["GLP1R (P43220)\nBeta cells, hypothalamus\nbrain NTS, heart"]
    end

    subgraph Signal["Gs / cAMP / PKA + Epac2"]
        Gs["Galpha-s activation"]
        AC["Adenylyl cyclase\n(ADCY5/6)"]
        cAMP["cAMP"]
        PKA_node["PKA\n(PRKACA/B)"]
        Epac2_node["Epac2 / Rap1\n(RAPGEF4)"]
        KATP["KATP channel closure\n(Kir6.2 / SUR1)"]
        CaV["L-type Ca2+ channels\n(Cav1.2 / Cav1.3)"]
        Exo["Insulin granule exocytosis\n(SNARE complex)"]
        CREB_node["CREB Ser133-P\nbeta-cell gene transcription"]
    end

    subgraph Outputs["Physiological Outputs"]
        INS["Insulin secretion\n(glucose-dependent)"]
        GCG_sup["Glucagon suppression\n(alpha cells, GLP1R)"]
        Satiety["Satiety / appetite suppression\n(hypothalamus, NTS)"]
        GE["Gastric emptying delay\n(vagal efferents)"]
        Cardio["Cardiac protection\nHR, contractility\n(GLP1R in myocardium)"]
        Bone["Bone turnover\n(GIPR in osteoblasts)"]
        FatGIP["Adipose lipogenesis /\nfat deposition\n(GIPR in adipocytes)"]
    end

    subgraph Compounds["Research Compounds"]
        Sema["Semaglutide\nGLP-1R monoagonist\nDPP-4 resistant"]
        Tirze["Tirzepatide\nGLP-1R + GIPR dual agonist\nbiased GLP-1R signaling"]
        Reta["Retatrutide\nGLP-1R + GIPR + GCGR\ntriple agonist"]
    end

    K --> GIP_lig
    L --> GLP1_lig
    GLP1_lig -->|"rapid inactivation"| DPP4
    GIP_lig -->|"rapid inactivation"| DPP4

    GIP_lig --> GIPR_r
    GLP1_lig --> GLP1R_r

    GIPR_r --> Gs
    GLP1R_r --> Gs
    Gs --> AC
    AC --> cAMP
    cAMP --> PKA_node
    cAMP --> Epac2_node
    PKA_node --> KATP
    Epac2_node --> KATP
    KATP --> CaV
    CaV --> Exo
    PKA_node --> CREB_node
    Exo --> INS

    GLP1R_r --> GCG_sup
    GLP1R_r --> Satiety
    GLP1R_r --> GE
    GLP1R_r --> Cardio
    GIPR_r --> Bone
    GIPR_r --> FatGIP

    Sema --> GLP1R_r
    Tirze --> GLP1R_r
    Tirze --> GIPR_r
    Reta --> GLP1R_r
    Reta --> GIPR_r
    Reta -->|"GCGR activation"| Outputs

Physiological Outputs

Glucose-Dependent Insulin Secretion

The defining feature of incretin signaling is glucose-dependency. At fasting glucose concentrations, KATP channels remain open, beta-cell membrane potential is hyperpolarized, and cAMP elevation by incretins produces only a minor increase in insulin output. As blood glucose rises after a meal, KATP channels begin to close through the canonical ATP/ADP-sensing mechanism, partially depolarizing the membrane. Incretin-driven cAMP then amplifies the calcium signal through Epac2/Rap1-mediated KATP closure and PKA-dependent sensitization of exocytic machinery, generating a multiplicative, not merely additive, increase in insulin secretion. This glucose-dependence mechanism explains why GLP-1R agonists carry a substantially lower intrinsic hypoglycemia risk than sulfonylureas, which close KATP channels constitutively. (PMID 17098089)

Glucagon Suppression

GLP1R is expressed on pancreatic alpha cells at lower density than on beta cells. GLP-1 suppresses glucagon secretion directly through alpha-cell GLP1R and indirectly through paracrine signaling from beta-cell insulin and delta-cell somatostatin. This dual action on both insulin secretion and glucagon suppression produces a coordinated reduction in hepatic glucose output, a critical component of postprandial glucose control. GIP, by contrast, stimulates glucagon release from alpha cells through GIPR at hypoglycemic glucose concentrations, providing a counterregulatory role distinct from GLP-1. (PMID 33289908)

Satiety, Food Intake, and Body Weight

GLP-1 produced by brainstem NTS neurons and circulating GLP-1 reaching the hypothalamus both activate GLP1R on arcuate nucleus and paraventricular nucleus (PVN) neurons to reduce food intake and increase satiety. GLP1R-expressing neurons in the NTS project to the lateral parabrachial nucleus (lPBN), a hub that integrates visceral satiety signals; activation of this circuit produces aversion to overconsumption. (PMID 32325333)

In the arcuate nucleus, GLP-1R co-localizes with leptin receptors on POMC neurons, creating convergence between the incretin and melanocortin axes. GIPR is also expressed in hypothalamic neurons, and CNS GIPR signaling contributes to energy balance independently of beta-cell effects; rodent studies demonstrate that brain-specific GIPR deletion reduces the anorectic efficacy of exogenous GIP. (PMC8576424)

Gastric vagal afferents express GLP1R; receptor activation slows gastric emptying via vagal efferent pathways, extending the duration of postprandial satiety signaling and attenuating the rate of glucose absorption.

Cardiovascular Effects

The LEADER trial (semaglutide predecessor liraglutide, NCT01179048) and the SELECT trial (semaglutide, NCT03574597) demonstrated cardiovascular risk reduction in GLP-1R agonist-treated populations with established cardiovascular disease or high cardiovascular risk. GLP1R is expressed in ventricular cardiomyocytes and coronary vascular endothelium; GLP-1R activation increases heart rate, augments myocardial contractility through cAMP/PKA-dependent phosphorylation of phospholamban and troponin I, and reduces ischemia-reperfusion injury in preclinical models. The mechanisms underlying clinical cardiovascular benefit are likely multifactorial: direct cardiac effects, blood pressure reduction, weight loss, improved lipid profiles, and renal protective effects all contribute. (PMID 35940765)

GIPR is expressed in cardiac tissue and vascular smooth muscle at lower levels. The cardiovascular consequences of GIPR activation remain under investigation; dedicated cardiovascular outcome trials for tirzepatide and retatrutide are ongoing (NCT04255433 SURPASS-CVOT; NCT04748835).

Adipose Tissue and Bone

GIPR in adipocytes promotes lipid uptake and triglyceride storage in the postprandial state. This lipid-buffering function prevents ectopic fat deposition in liver and muscle under normal nutrient conditions. In the context of obesity, chronic GIPR activation may contribute to adipose expansion; however, GIPR agonism in combination with GLP-1R agonism produces net weight loss in humans, suggesting that the central anorectic and metabolic effects dominate the peripheral adipogenic signal. (PMID 36050763)

GIPR on osteoblasts and osteoclasts modulates bone turnover markers. GIP suppresses bone resorption and augments bone formation in short-term clinical studies. Whether long-term GIPR-targeting therapies affect fracture risk remains an open question.

Related Compounds

Semaglutide

Semaglutide is a long-acting GLP-1 analogue modified by fatty diacid attachment via a C18 linker to Lys26, enabling reversible albumin binding that extends plasma half-life to approximately 165-184 hours (once-weekly dosing). Two amino acid substitutions (Aib8 replacing Ala8, and Arg34 replacing Lys34) confer DPP-4 resistance. Semaglutide is a selective GLP1R agonist with no meaningful activity at GIPR or the glucagon receptor (GCGR).

At the receptor level, semaglutide produces full Gs activation and cAMP accumulation in beta cells, hypothalamic GLP1R-expressing neurons, and cardiac myocytes. In the SUSTAIN and STEP clinical trial programs, subcutaneous semaglutide 2.4 mg once weekly produced mean body weight reductions of 14.9-17.4% over 68 weeks in individuals with obesity without T2D (PMID 33567185). In the SELECT trial (NCT03574597), semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in 17,604 adults with overweight/obesity and established cardiovascular disease without T2D. (PMID 37937007)

Research hub: Semaglutide Research

Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual GLP-1R and GIPR co-agonist. Its sequence is based on the GIP backbone with a C20 fatty diacid at Lys20 for albumin binding (half-life approximately 5 days) and a tyrosine amide at the C-terminus. At human receptors, tirzepatide is potent at GIPR (EC50 approximately 0.060 nM), with somewhat lower potency at GLP1R (EC50 approximately 0.40 nM). Crucially, tirzepatide acts as a functionally biased agonist at GLP1R, recruiting less beta-arrestin 2 relative to the cAMP response compared with native GLP-1 or semaglutide. This biased profile may reduce GLP1R desensitization in relevant tissues and contribute to superior weight loss. (PMID 36050763)

In the SURMOUNT-1 trial (NCT04184622), tirzepatide 15 mg produced a mean 20.9% reduction in body weight versus placebo at 72 weeks. In the SURPASS-2 trial, tirzepatide outperformed semaglutide 1.0 mg in HbA1c reduction and weight loss. FDA approved tirzepatide for T2D (Mounjaro, 2022) and for obesity/overweight (Zepbound, 2023).

Research hub: Tirzepatide Research

Retatrutide

Retatrutide (LY3437943) is a novel triple receptor agonist with activity at GLP1R (EC50 approximately 0.775 nM), GIPR (EC50 approximately 0.064 nM), and the glucagon receptor (GCGR, gene GCGR, UniProt P47871; EC50 approximately 5.79 nM). The addition of GCGR agonism to the incretin axis engagement provides two further mechanisms: hepatic glucose output suppression (acutely), and enhanced thermogenesis and lipolysis in adipose tissue through cAMP/PKA in hepatocytes and brown adipose. GCGR-driven metabolic rate increases complement the GLP-1R- and GIPR-mediated appetite suppression, potentially accounting for retatrutide’s exceptional weight loss signal.

In a Phase 2 trial (NCT04881760), retatrutide at 12 mg produced a mean body weight reduction of 24.2% at 48 weeks in adults with obesity without T2D, with 36-48% of participants losing 25% or more of body weight. In the companion T2D cohort, HbA1c improved by 2.2% with 82% reaching HbA1c at or below 6.5%. Phase 3 trials are ongoing. (PMC12190491)

Research hub: Retatrutide Research

Key Molecular Targets Summary

Primary Literature

Pathway Context

The incretin axis interfaces with several adjacent signaling networks. PKA-dependent CREB activation in beta cells parallels the CREB phosphorylation seen downstream of the MAPK Cascade (/pathways/mapk-cascade/), where ERK1/2 provides a second kinase capable of CREB Ser133 phosphorylation; these two paths converge on overlapping gene programs supporting beta-cell proliferation and survival. GLP-1R-driven PI3K/Akt signaling in beta cells and neurons connects to the PI3K-Akt Pathway (/pathways/pi3k-akt-pathway/), through which incretins inhibit FOXO1 transcriptional activity and reduce apoptotic gene expression. The GCGR arm of retatrutide activates hepatic cAMP, which feeds into mitochondrial fatty acid oxidation programs described in the Mitochondrial Function pathway (/pathways/mitochondrial-function/). Together, these interconnections explain why incretin-targeting therapies produce metabolic benefits spanning glycemic control, body weight, hepatic fat, and cardiovascular risk that extend well beyond their canonical beta-cell pharmacology.

See also

Compounds that engage this pathway:

• Semaglutide
• Tirzepatide
• Retatrutide